What happened
FDA cited significant CGMP violations following an April 2026 inspection of Hanlim Pharm’s drug manufacturing facility. Inspectors observed poor aseptic practices, including operators obstructing first air, working directly over exposed components, and wearing a visibly stained gown. Dynamic smoke studies did not demonstrate adequate unidirectional airflow protection and indicated possible entrainment of lower-quality air into the ISO 5 processing line. FDA also found that critical container-closure contact surfaces were wiped with sporicidal disinfectants rather than sterilized. Environmental monitoring locations and frequencies were not adequately justified or sufficient to detect contamination risks near containers, closures, and barriers facing ISO 5 areas. The visual inspection program lacked routine defect categorization and appropriate acceptance criteria despite significant defect rates. FDA further stated that the quality unit lacked adequate authority and oversight, citing failures involving the stability program and contemporaneous documentation of environmental and personnel monitoring data. FDA considered the company’s responses inadequate and noted similar violations in a previous warning letter.
Why it matters
The observations may undermine sterility assurance because deficient operator practices, airflow protection, equipment sterilization, and environmental monitoring can permit contamination hazards to remain uncontrolled or undetected. Weak visible-particle inspection may limit reliable detection and investigation of foreign matter. Inadequate quality-unit authority, stability oversight, and contemporaneous records may also impair batch disposition, expiration-date support, investigation oversight, and confidence in manufacturing and laboratory data. FDA described these findings as evidence of an ineffective quality system and inadequate executive management oversight.
Key topics: Poor aseptic practices and deficient dynamic smoke studies, Inadequate sterilization, environmental monitoring, and visual inspection controls, Ineffective quality unit oversight and non-contemporaneous monitoring records